Impact of frailty on health-related quality of life 1 year after transcatheter aortic valve implantation.
Aortic stenosis (AS)
EQ-5D
Frailty
Mortality
Older people
Quality of life
Transcatheter aortic valve implantation (TAVI)
Journal
Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655
Informations de publication
Date de publication:
23 10 2020
23 10 2020
Historique:
received:
25
10
2019
pubmed:
19
5
2020
medline:
29
7
2021
entrez:
19
5
2020
Statut:
ppublish
Résumé
Transcatheter aortic valve implantation (TAVI) brings symptom relief and improvement in health-related quality of life (HRQoL) in the majority of patients treated for symptomatic, severe aortic stenosis. However, there is a substantial group of patients that do not benefit from TAVI. The aim of this study is to investigate the impact of frailty on HRQoL 1 year after TAVI. The TAVI Care & Cure Program is an ongoing, prospective, observational study including patients referred for TAVI to our institution. A comprehensive geriatric assessment was performed to evaluate existence of frailty using the Erasmus Frailty Score (EFS). HRQoL was assessed using the EQ-5D-5 L at baseline and 1 year after TAVI. 239 patients underwent TAVI and completed HRQoL assessment 1 year after TAVI. Seventy (29.3%) patients were classified as frail (EFS ≥ 3). In non-frail patients, the EQ-5D-5 L index did not change (0.71(± 0.22) to 0.68(± 0.33) points, P = 0.22); in frail patients, the EQ-5D-5 L index decreased from 0.55(±0.26) to 0.44 points (±0.33) (P = 0.022). Frailty was an independent predictor of deteriorated HRQoL 1 year after TAVI (OR 2.24, 95% CI 1.07-4.70, P = 0.003). In frail patients, the absence of peripheral artery disease (OR 0.17, 95% 0.05-0.50, P = 0.001) and renal dysfunction (OR 0.13, 95% CI 0.04-0.41, P = <0.001) at baseline was associated with improved HRQoL 1 year after TAVI. Frailty is associated with deterioration of HRQoL 1 year after TAVI. Notably, HRQoL did improve in frail patients with no peripheral arterial disease or renal impairment at baseline.
Sections du résumé
BACKGROUND
Transcatheter aortic valve implantation (TAVI) brings symptom relief and improvement in health-related quality of life (HRQoL) in the majority of patients treated for symptomatic, severe aortic stenosis. However, there is a substantial group of patients that do not benefit from TAVI. The aim of this study is to investigate the impact of frailty on HRQoL 1 year after TAVI.
METHODS
The TAVI Care & Cure Program is an ongoing, prospective, observational study including patients referred for TAVI to our institution. A comprehensive geriatric assessment was performed to evaluate existence of frailty using the Erasmus Frailty Score (EFS). HRQoL was assessed using the EQ-5D-5 L at baseline and 1 year after TAVI.
RESULTS
239 patients underwent TAVI and completed HRQoL assessment 1 year after TAVI. Seventy (29.3%) patients were classified as frail (EFS ≥ 3). In non-frail patients, the EQ-5D-5 L index did not change (0.71(± 0.22) to 0.68(± 0.33) points, P = 0.22); in frail patients, the EQ-5D-5 L index decreased from 0.55(±0.26) to 0.44 points (±0.33) (P = 0.022). Frailty was an independent predictor of deteriorated HRQoL 1 year after TAVI (OR 2.24, 95% CI 1.07-4.70, P = 0.003). In frail patients, the absence of peripheral artery disease (OR 0.17, 95% 0.05-0.50, P = 0.001) and renal dysfunction (OR 0.13, 95% CI 0.04-0.41, P = <0.001) at baseline was associated with improved HRQoL 1 year after TAVI.
CONCLUSION
Frailty is associated with deterioration of HRQoL 1 year after TAVI. Notably, HRQoL did improve in frail patients with no peripheral arterial disease or renal impairment at baseline.
Identifiants
pubmed: 32421189
pii: 5829706
doi: 10.1093/ageing/afaa071
pmc: PMC7583518
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
989-994Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society.
Références
Phys Ther. 2002 Feb;82(2):128-37
pubmed: 11856064
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Rev Esp Cardiol (Engl Ed). 2018 Feb;71(2):110
pubmed: 29425605
Ned Tijdschr Geneeskd. 2014;158:A7768
pubmed: 25308222
Qual Life Res. 2017 May;26(5):1197-1208
pubmed: 27796774
Am J Cardiol. 2015 Jul 15;116(2):264-9
pubmed: 25963221
J Am Geriatr Soc. 2004 Apr;52(4):625-34
pubmed: 15066083
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Am Fam Physician. 2016 Mar 1;93(5):371-8
pubmed: 26926974
Neth Heart J. 2013 Jan;21(1):21-7
pubmed: 23229811
Circulation. 2014 Jun 24;129(25):2682-90
pubmed: 24958751
Value Health. 2016 Jun;19(4):343-52
pubmed: 27325326
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Am Coll Cardiol. 2014 May 20;63(19):1972-81
pubmed: 24657695
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2541-2554
pubmed: 28007203
Clin Res Cardiol. 2015 Oct;104(10):877-86
pubmed: 25896479
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Geriatr Cardiol. 2018 Apr;15(4):261-267
pubmed: 29915615
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
Lancet. 2015 Jun 20;385(9986):2477-84
pubmed: 25788234
JACC Cardiovasc Interv. 2012 Sep;5(9):974-81
pubmed: 22995885
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
Int J Cardiol. 2019 Feb 1;276:48-52
pubmed: 30409734
J Gerontol A Biol Sci Med Sci. 2004 Mar;59(3):255-63
pubmed: 15031310
Front Cardiovasc Med. 2018 Jul 12;5:92
pubmed: 30050909
Arch Gerontol Geriatr. 2012 Jan-Feb;54(1):21-7
pubmed: 21371760
JAMA Cardiol. 2017 Apr 1;2(4):409-416
pubmed: 28146260
Expert Rev Cardiovasc Ther. 2016 Dec;14(12):1315-1323
pubmed: 27636535
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Am Geriatr Soc. 1995 Feb;43(2):130-7
pubmed: 7836636
EuroIntervention. 2010 May;6 Suppl G:G6-G13
pubmed: 20542831
Int J Cardiol. 2020 Mar 1;302:36-41
pubmed: 31859111
J Am Coll Cardiol. 2014 Mar 4;63(8):747-62
pubmed: 24291279
Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):697-704
pubmed: 22949492